CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz Abo ...

Core Insights - Skyward Specialty Insurance Group reported a significant increase in net income for Q4 2025, reaching $43.2 million, or $1.03 per diluted share, compared to $14.4 million, or $0.35 per diluted share in Q4 2024 [1][20] - For the full year 2025, net income was $170.0 million, or $4.07 per diluted share, up from $118.8 million, or $2.87 per diluted share in 2024 [1][20] Financial Performance - Adjusted operating income for Q4 2025 was $48.9 million, or $1.17 per diluted share, compared to $33.2 million, or $0.80 per diluted share in Q4 2024, marking a substantial year-over-year increase [2][21] - The full year adjusted operating income for 2025 was $167.4 million, or $4.00 per diluted share, compared to $126.6 million, or $3.06 per diluted share in 2024 [2][21] Underwriting Results - Gross written premiums for Q4 2025 were $439.5 million, a 13.2% increase from $388.4 million in Q4 2024, while total gross written premiums for the year reached $2.17 billion, up 24.3% from $1.74 billion in 2024 [3][5] - The combined ratio improved to 88.5% in Q4 2025 from 95.8% in Q4 2024, indicating better underwriting performance [4][5] Investment Results - Net investment income for Q4 2025 increased to $23.5 million from $20.7 million in Q4 2024, driven by higher yields from the fixed income portfolio [7][20] - For the full year, net investment income rose to $83.6 million from $80.6 million in 2024 [7][20] Equity and Book Value - Stockholders' equity increased to $1,009.6 million at December 31, 2025, a 5.0% rise from $961.4 million at September 30, 2025, primarily due to net income and an increase in the market value of the investment portfolio [9][26] - Book value per share reached $24.92, reflecting a 26% increase compared to $19.79 at the end of 2024 [5][22] Strategic Outlook - The company emphasized its "Rule Our Niche" strategy, focusing on a diversified portfolio with nearly half of its business in non-cycle exposed lines, positioning it well for future growth in the specialty insurance market [2][5]

Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14: ...

Welcomes Long-Overdue Acknowledgment of Stockholder Concerns Calls for Recusal of 10X-Affiliated Directors from AMA Discussions and Full Public Disclosure of Proposed AMA Amendments Reaffirms the Importance of Board Independence and Protection of Stockholder Rights ROAD TOWN, British Virgin Islands, Feb. 23, 2026 (GLOBE NEWSWIRE) -- YZILabs Management Ltd. (“YZi Labs”, “YZi”, “we”), a significant stockholder of CEA Industries Inc. (NASDAQ: BNC) (“BNC” or the “Company”), today issued the below statement in r ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...

SYDNEY, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Resolution Mineral Ltd. (ASX:RML; OTC: RLMLF) today announced that Craig Lindsay, CEO of US Operations, will present live at Australia Investor Day hosted by VirtualInvestorConferences.com and OTC Markets Group, on February 26th, 2026. DATE: February 26th TIME: 2:15 PM ET REGISTER HERE To schedule a virtual 1x1 meeting, please click here. To schedule an in-person 1x1 meeting, please click here. This will be a live, interactive in-person and online event where invest ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...

Fourth Quarter 2025 Revenues of $345.1 Million Reflect 21.9 Percent Growth and 20.0 Percent Organic Growth Over Fourth Quarter 2024 Revenues of $283.1 Million Unmanned Systems Fourth Quarter 2025 Revenues of $68.5 Million Reflect 12.1 Percent Organic Growth Over Fourth Quarter 2024 Revenues of $61.1 Million Kratos Government Solutions Fourth Quarter 2025 Revenues of $276.6 Million Reflect 22.2 Percent Organic Growth Over Fourth Quarter 2024 Revenues of $222.0 Million Fourth Quarter 2025 Consolidated Book to ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus i ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oracle investors who were adversely affected by alleged securities fraud between June 12, 2025 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/oracle-corporation-lawsuit-su ...